 BOSTON--BUSINESS WIRE--Ironwood Pharmaceuticals, Inc. Nasdaq: IRWD, a GI-focused healthcare company, today provided an update on its third quarter 2020 results and recent business performance. Ironwoods strong financial performance this quarter was bolstered by continued demand for our market leading product LINZESS, which delivered 10 growth in net sales year-over-year, and another quarter of profitability and positive cash flow for Ironwood, said Mark Mallon, chief executive officer o 